Richard Pascoe takes the helm at Histogen; Lonza COO steps up at CEO Richard Ridinger retires

Richard Pascoe

? Having handed off troubled microcap biotech Apricus Biosciences to Seelos Therapeutics via a merger, Richard Pascoe is moving on to his next CEO (and chairman) gig at Histogen. The regenerative medicine developer is anticipating data from a clinical trial in female hair loss this year, and the board likes Pascoe?s experience in both fundraising and regulatory dealings. Pascoe also appears to have a penchant for companies that get absorbed, including Somaxon Pharma